Pharmaceutical Technology Europe, May 3, 2011 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, May 3, 2011
Editor's Comment
Inter city tales
By Rich Whitworth
As I strolled through Times Square, famous brand coffee cup in hand, towards the Jacob K. Javits Convention Center in New York, my thoughts were entirely focused on Interphex.
Special Feature
Packaging Considerations
By Stephen Kemp
There are a number of points to consider where secondary packaging is concerned.
Is Pharma's Language Too Confusing?
By Dk Theo Rayner
Research conducted in the UK by the University of Leeds and Luto Research shows that many commonly-used phrases on medicine labels are easily misunderstood.
Extending Shelf-Life With Sorbents
By Adrian Possumato
Extending a drug product's shelf life while maintaining its strength, quality and purity is a challenge for pharma companies.
Improving Packaging Security
By Chris Halling
Legislation has prompted the pharma industry to seek technologies that can be used to secure a product throughout the supply chain.
Meeting New Packaging And Coding Requirements
By Craig Stobie
More challenges face the pharma packaging industry today than ever before, according to Domino Printing Sciences' global life sciences sector manager.
The Relationship Between Packaging And The Patient
By Tim Clarke
In light of the challenges facing the pharma industry, such as changing patient demands and changing demographics, the relationship between the packaging, the consumer and the product is being completely reconsidered.
Peer-Reviewed Research
Gelatin Capsule Shell Cross-Linking
The authors develop a pratical approach to avoid unwanted interactions between pepsin and SLS in dissolution Tier II tests.
Pharmaceutical Excipients For Hot-Melt Extrusion
The authors examine the influence of glass-transition temperature, melt viscosity, degredation temperature, and process settings.
Industry Insider
Could The UK Be Losing Its Pharma Luster?
By Nathan Jessop
Despite initiatives to encourage multinational pharma companies to conduct R&D in the UK, the country may be losing its edge; is Pfizer's decision to exit a key site earlier this year the beginning of a mass exodus?
Adapting To New Pressures And The Emerging Markets
By Gilles Cottier
A large CMO explains its strategies for expanding into the emerging markets.
By Stephanie Sutton
Outsourcing can have its benefits, but how often do we bother to measure the actual value of our outsourcing relationships?


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here